Preventing Fungal Infections in High Risk Patients.

 
candida-albicans.jpg

AVnovum is developing a new class of antimicrobial therapy, AVpeptides, that maintain healthy fungal microbiomes by preventing virulence and infection. AVpeptides work through mechanisms that specifically target virulent but not health-promoting microbes. AVnovum is driven by a diverse team of research scientists and advisors with scientific, entrepreneurial, and business backgrounds, who are dedicated to improving patient outcomes in those with diabetes, immunodeficiencies, and immunosuppression.

 
 
440px-Harper_Midway_Chicago.jpg

Commercialized through the University of Chicago

Learn more about our story and team.